ATM and neoplasm: M4076, an ATP-competitive ATM inhibitor with an IC50 value <1 nM, inhibits tumor cell growth by blocking DSB repair and enhances the sensitivity of tumor cells to radiation therapy both in vitro and in vivo.1258,1259 A phase I clinical trial of M4076 in advanced solid tumors is active (NCT04882917).